Record Information |
---|
Version | 2.0 |
---|
Creation Date | 2009-07-21 20:28:34 UTC |
---|
Update Date | 2014-12-24 20:25:55 UTC |
---|
Accession Number | T3D3010 |
---|
Identification |
---|
Common Name | Fluoxymesterone |
---|
Class | Small Molecule |
---|
Description | Fluoxymesterone is only found in individuals that have used or taken this drug. It is an anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women. [PubChem] Fluoxymesterone is a synthetic androgenic anabolic steroid and is approximately 5 times as potent as natural methyltestosterone. Like testosterone and other androgenic hormones, fluoxymesterone binds to the androgen receptor. It produces retention of nitrogen, sodium, potassium, and phosphorus; increases protein anabolism; decreases amino acid catabolism and decreased urinary excretion of calcium. The antitumour activity of fluoxymesterone appears related to reduction or competitive inhibition of prolactin receptors or estrogen receptors or production. |
---|
Compound Type | - Anabolic Agent
- Antineoplastic Agent, Hormonal
- Drug
- Ester
- Metabolite
- Organic Compound
- Organofluoride
- Synthetic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Synonym | 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one | 17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone | 17α-Methyl-9α-fluoro-11β-hydroxytesterone | 9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one | 9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone | Androfluorene | Androfluorone | Androxy | Fluossimesterone | Fluoximesterona | Fluoximesterone | Fluoximesteronum | Fluoxymesteronum | Fluoxymestrone | Halotestin | Ora-Testryl | Testoral | U-Gono | UItandren |
|
---|
Chemical Formula | C20H29FO3 |
---|
Average Molecular Mass | 336.441 g/mol |
---|
Monoisotopic Mass | 336.210 g/mol |
---|
CAS Registry Number | 76-43-7 |
---|
IUPAC Name | (1R,2S,10S,11S,14S,15S,17S)-1-fluoro-14,17-dihydroxy-2,14,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one |
---|
Traditional Name | fluoxymesterone |
---|
SMILES | [H][C@@]12CC[C@](C)(O)[C@@]1(C)C[C@]([H])(O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)CC[C@]12C |
---|
InChI Identifier | InChI=1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1 |
---|
InChI Key | InChIKey=YLRFCQOZQXIBAB-RBZZARIASA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Androstane steroids |
---|
Direct Parent | Androgens and derivatives |
---|
Alternative Parents | |
---|
Substituents | - Androgen-skeleton
- 3-oxo-delta-4-steroid
- 3-oxosteroid
- 17-hydroxysteroid
- 11-hydroxysteroid
- 11-beta-hydroxysteroid
- Oxosteroid
- 9-halo-steroid
- Halo-steroid
- Hydroxysteroid
- Delta-4-steroid
- Cyclohexenone
- Cyclic alcohol
- Tertiary alcohol
- Cyclic ketone
- Secondary alcohol
- Fluorohydrin
- Halohydrin
- Ketone
- Alcohol
- Organic oxide
- Organic oxygen compound
- Carbonyl group
- Hydrocarbon derivative
- Alkyl halide
- Organooxygen compound
- Organofluoride
- Organohalogen compound
- Alkyl fluoride
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | - Cytoplasm
- Extracellular
- Membrane
|
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | |
---|
Biological Roles | |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Appearance | White powder. |
---|
Experimental Properties | Property | Value |
---|
Melting Point | 265°C | Boiling Point | Not Available | Solubility | 67.5 mg/L | LogP | 2.38 |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | Deposition Date | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-0ab9-1934000000-8eb342128d6bf9311319 | 2017-09-01 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (2 TMS) - 70eV, Positive | splash10-00ou-0951400000-91106f5e4565733878fe | 2017-10-06 | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-014r-0019000000-48934627a15489915ee8 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-014r-0289000000-97f81d1c3434cd2ebf78 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0udi-3294000000-6727e66346d908d21d94 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-000i-0009000000-8fa1a3bcb20d7e11f56c | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-00kr-0009000000-e763c698cec90ff489d4 | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-00mo-0596000000-4dd2e6ac91164ea740ce | 2016-08-03 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-00kr-0019000000-e06c0ac56f323c20416a | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-004u-2594000000-7ce7c92338e057214383 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-05ec-5940000000-063fa6a84fc098f79fca | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-000i-0009000000-f77bab0fc5505f2a76bd | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-000i-0029000000-47936a6dd33f48e53957 | 2021-10-11 | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-014r-2239000000-4e814ffc32e746f27d3f | 2021-10-11 | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-006x-5951000000-4c37d94fe4ed0b343941 | 2014-09-20 | View Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | Oral absorption is less than 44%. |
---|
Mechanism of Toxicity | Fluoxymesterone is a synthetic androgenic anabolic steroid and is approximately 5 times as potent as natural methyltestosterone. Like testosterone and other androgenic hormones, fluoxymesterone binds to the androgen receptor. It produces retention of nitrogen, sodium, potassium, and phosphorus; increases protein anabolism; decreases amino acid catabolism and decreased urinary excretion of calcium. The antitumour activity of fluoxymesterone appears related to reduction or competitive inhibition of prolactin receptors or estrogen receptors or production. |
---|
Metabolism | Presence of 17-alpha alkyl group reduces susceptibility to hepatic enzyme degradation, which slows metabolism and allows oral administration. Inactivation of testosterone occurs primarily in the liver
Half Life: 9.2 hours |
---|
Toxicity Values | Not Available |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
---|
Uses/Sources | In males, used as replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. In females, for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Not Available |
---|
Symptoms | Side effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia. |
---|
Treatment | Not Available |
---|
Normal Concentrations |
---|
| Not Available |
---|
Abnormal Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB01185 |
---|
HMDB ID | HMDB15316 |
---|
PubChem Compound ID | 6446 |
---|
ChEMBL ID | CHEMBL1445 |
---|
ChemSpider ID | 6205 |
---|
KEGG ID | Not Available |
---|
UniProt ID | Not Available |
---|
OMIM ID | |
---|
ChEBI ID | 5120 |
---|
BioCyc ID | Not Available |
---|
CTD ID | Not Available |
---|
Stitch ID | Fluoxymesterone |
---|
PDB ID | Not Available |
---|
ACToR ID | Not Available |
---|
Wikipedia Link | Fluoxymesterone |
---|
References |
---|
Synthesis Reference | U.S. Patent 2,793,218
U.S. Patent 2,813,881 |
---|
MSDS | Link |
---|
General References | - Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, Lopez FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A: An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73. Epub 2006 Oct 5. [17023534 ]
|
---|
Gene Regulation |
---|
Up-Regulated Genes | Not Available |
---|
Down-Regulated Genes | Not Available |
---|